ArticlePloS one2015
SELEX aptamer used as a probe to detect circulating tumor cells in peripheral blood of pancreatic cancer patients.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Aptamers Targeting Membrane Proteins for Sensor and Diagnostic Applications.Molecules (Basel, Switzerland) · 2023Review
- Aptamers as Theragnostic Tools in Prostate Cancer.Biomolecules · 2022Review
- Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.Radiation oncology (London, England) · 2020Review
- Graphene-based biosensors for the detection of prostate cancer protein biomarkers: a review.BMC chemistry · 2019Review
- Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.Molecular oncology · 2019Review
- The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer.International journal of molecular sciences · 2019Review
- Microfluidics for studying metastatic patterns of lung cancer.Journal of nanobiotechnology · 2019Review
- Clinical significance of circulating tumor cells via combined whole exome sequencing in early stage cancer screening: A case report.Experimental and therapeutic medicine · 2018Article
- An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters.Scientific reports · 2018Article
- Review
- Enrichment and single-cell analysis of circulating tumor cells.Chemical science · 2017Article
- Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.World journal of gastroenterology · 2016Review
- Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization.Journal of experimental & clinical cancer research : CR · 2016Article
- Oligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells.Methods (San Diego, Calif.) · 2016Review
- Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.BioTechniques · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies have shown that the quantity and dynamics of circulating tumor cells (CTCs) in peripheral blood of patients afflicted with solid tumours have great relevance in therapeutic efficacy and prognosis. Different methods based on various strategies have been developed to isolate and identify CTCs, but their efficacy needs to be improved because of the rarity and complexity of CTCs. This study was designed to examine the possibility of using a SELEX aptamer (BC-15) as a probe to identify rare CTCs out of background nucleated cells. Aptamer BC-15 was selected from a random oligonucleotide library screened against human breast cancer tissue. Fluorescence staining showed that BC-15 had a high affinity for nuclei of human cancer cell lines of various origins as well as CTCs isolated from pancreatic cancer patients, whereas its binding capacity for non-tumor breast epithelial cells and leukocytes was almost undetectable. BC-15+/CD45- cells in cancer patient blood were also found to be cytokeratins 18-positive and aneuploid by immunofluorescence staining and fluorescent in situ hybridization, respectively. Finally, the aptamer method was compared with the well-established anti-cytokeratin method using 15 pancreatic cancer patient blood samples, and enumeration indicated no difference between these two methods. Our study establishes a novel way to identify CTCs by using a synthetic aptamer probe. This new approach is comparable with the anti-cytokeratin-based CTC identification method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.